Somewhat Positive Press Coverage Somewhat Unlikely to Impact GlaxoSmithKline (GSK) Share Price

Headlines about GlaxoSmithKline (NYSE:GSK) have been trending somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the pharmaceutical company an impact score of 44.9382790347023 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

A number of analysts have weighed in on GSK shares. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, October 18th. Morgan Stanley downgraded shares of GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. Argus reissued a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline in a research report on Thursday, August 31st. TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 24th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $39.71.

GlaxoSmithKline (NYSE GSK) traded down $0.14 during trading on Wednesday, hitting $34.86. The company’s stock had a trading volume of 5,995,300 shares, compared to its average volume of 3,498,092. The company has a market cap of $86,076.94, a PE ratio of 12.41, a price-to-earnings-growth ratio of 1.94 and a beta of 0.98. GlaxoSmithKline has a 52-week low of $34.72 and a 52-week high of $44.53. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.78%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is presently 163.12%.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://stocknewstimes.com/2017/12/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-glaxosmithkline-gsk-share-price.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply